The ratio of phosphorylated GSK-3β at Ser9 (the inhibitory site of its activity) to total GSK-3β was significantly higher in the SMC- and SeM-treated AD mice than in the untreated AD mice, whereas there was an upward trend in the SeNa group (Figure 5a,b). This evidence concerns the gene GSK3B and Alzheimer disease.